A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Kiwon Ban, M. Hossein Noyan-Ashraf, Judith Hoefer et al. · Circulation · 2008 · 1K citations

Medicine, Cardiology, Pharmacology +17

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Thomas Nyström, M. Gutniak, Qimin Zhang et al. · American Journal of Physiology-Endocrinology and Metabolism · 2004 · 671 citations

Medicine, Cardiology, Endocrinology +17

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

M. Hossein Noyan-Ashraf, M. Abdul Momen, Kiwon Ban et al. · Diabetes · 2009 · 572 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Masayuki Arakawa, Tomoya Mita, Kosuke Azuma et al. · Diabetes · 2010 · 536 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice

Naim Panjwani, Erin E. Mulvihill, Christine Longuet et al. · Endocrinology · 2012 · 346 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17